Extract from Chairman's letter to shareholder's for rights issue.
"Invion is currently completing its INV103 (ala-Cpn10) and INV102 (nadolol) programs, with pivotal data anticipated within three to four months. Based on recent transactions in the industry it is anticipated that this data will enable the Company to negotiate a strategic investment by a recognised biotech fund, or provide a platform for the sale of the Company or its assets within six months. "
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.59M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.5¢ | 12.5¢ | $15.62K | 118.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 213400 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 57707 | 2 |
View Market Depth
| Last trade - 14.46pm 20/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |